BMRN
BioMarin PharmaceuticalCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bullish read is that BioMarin now has a faster-growing commercial portfolio after the Amicus close, raised 2026 revenue guidance materially, still has multiple near-term Phase 3 catalysts, and retains substantial valuation upside versus the packet’s median target near $89.5.
Posture
Mixed
Lead driver
Value
What changed
1 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Amicus integration raises execution risk just as management shifts 2026 revenue and EPS heavily into 2H.
Momentum
26
Value
66
Sentiment
59
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $58.00 · Bull $72.00 · Bear $44.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $89.45
Why
Momentum26 · Δ7d +0.7
Value66 · Δ7d +0.0
Sentiment59 · Δ7d +1.3
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
26
34% active weight
Current posture
7d trendFlat
Δ7d
+0.7
Δ21d
+11.5
Value
66
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.1
Sentiment
59
33% active weight
Current posture
7d trendImproving
Δ7d
+1.3
Δ21d
+3.3
Why this grade
Composite grade C. Momentum 26.4 / Value 65.6 / Sentiment 59.1
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$10.64B
Beta
0.26
Shares Out
192.11M
P/E (TTM)
22.1
P/S (TTM)
3.66
P/FCF (TTM)
13.70
Rev YoY
+4.1%
EPS YoY
-129.2%
Gross Margin
+81.3%
Op Margin
+19.9%
Net Debt
-$541.47M
Current Ratio
4.83
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology